Published in Nucleic Acids Res on July 27, 2013
Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol (2014) 1.84
Cancer evolution: mathematical models and computational inference. Syst Biol (2014) 1.36
BitPhylogeny: a probabilistic framework for reconstructing intra-tumor phylogenies. Genome Biol (2015) 1.22
PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors. Genome Biol (2015) 1.17
Inferring clonal composition from multiple sections of a breast cancer. PLoS Comput Biol (2014) 1.17
A combinatorial approach for analyzing intra-tumor heterogeneity from high-throughput sequencing data. Bioinformatics (2014) 1.14
SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol (2014) 1.12
An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Brief Bioinform (2014) 1.03
Tree inference for single-cell data. Genome Biol (2016) 0.97
Reconstruction of clonal trees and tumor composition from multi-sample sequencing data. Bioinformatics (2015) 0.96
A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. Genome Biol (2014) 0.96
SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing. PLoS Comput Biol (2015) 0.94
Reconstructing metastatic seeding patterns of human cancers. Nat Commun (2017) 0.92
Enhancing cancer clonality analysis with integrative genomics. BMC Bioinformatics (2015) 0.79
Tumor Evolution: Linear, Branching, Neutral or Punctuated? Biochim Biophys Acta (2017) 0.77
Computational Cancer Biology: An Evolutionary Perspective. PLoS Comput Biol (2016) 0.76
The Occurrence of Genetic Alterations during the Progression of Breast Carcinoma. Biomed Res Int (2016) 0.75
Ultra-fast local-haplotype variant calling using paired-end DNA-sequencing data reveals somatic mosaicism in tumor and normal blood samples. Nucleic Acids Res (2015) 0.75
phyC: Clustering cancer evolutionary trees. PLoS Comput Biol (2017) 0.75
Bayesian inference for intratumour heterogeneity in mutations and copy number variation. J R Stat Soc Ser C Appl Stat (2016) 0.75
FISHtrees 3.0: Tumor Phylogenetics Using a Ploidy Probe. PLoS One (2016) 0.75
Computational Methods for Characterizing Cancer Mutational Heterogeneity. Front Genet (2017) 0.75
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol (2009) 235.12
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Galaxy: a platform for interactive large-scale genome analysis. Genome Res (2005) 35.75
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
TCS: a computer program to estimate gene genealogies. Mol Ecol (2000) 27.89
The clonal evolution of tumor cell populations. Science (1976) 24.39
Learning the parts of objects by non-negative matrix factorization. Nature (1999) 21.77
Tumour evolution inferred by single-cell sequencing. Nature (2011) 19.13
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics (2009) 16.04
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Bayesian inference of phylogeny and its impact on evolutionary biology. Science (2001) 11.15
Clonal evolution in cancer. Nature (2012) 11.07
The life history of 21 breast cancers. Cell (2012) 10.59
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Fast and robust fixed-point algorithms for independent component analysis. IEEE Trans Neural Netw (1999) 10.23
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
A restricted cell population propagates glioblastoma growth after chemotherapy. Nature (2012) 8.88
Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature (2010) 8.48
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science (2012) 6.55
Metastasis results from preexisting variant cells within a malignant tumor. Science (1977) 6.47
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell (2004) 6.24
Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell (2012) 5.92
Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell (2012) 5.62
Parallel progression of primary tumours and metastases. Nat Rev Cancer (2009) 5.55
Two levels of protection for the B cell genome during somatic hypermutation. Nature (2008) 5.32
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell (2012) 5.16
Defining the mode of tumour growth by clonal analysis. Nature (2012) 5.02
Cell type-specific gene expression differences in complex tissues. Nat Methods (2010) 4.75
Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med (2009) 4.71
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A (2010) 4.47
Mutations induced by ultraviolet light. Mutat Res (2005) 4.45
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer (2010) 4.19
A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res (2008) 4.06
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Deciphering signatures of mutational processes operative in human cancer. Cell Rep (2013) 3.61
IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2005) 3.46
IMGT/HLA database--a sequence database for the human major histocompatibility complex. Tissue Antigens (2000) 3.41
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Adaptive therapy. Cancer Res (2009) 2.81
Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer (2011) 2.77
Evolution of resistance during clonal expansion. Genetics (2006) 2.36
The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci U S A (2011) 2.25
Inferring tree models for oncogenesis from comparative genome hybridization data. J Comput Biol (1999) 2.25
Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood (2008) 2.15
Sparse linear modeling of next-generation mRNA sequencing (RNA-Seq) data for isoform discovery and abundance estimation. Proc Natl Acad Sci U S A (2011) 2.05
Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol (2009) 1.97
Estimation of rearrangement phylogeny for cancer genomes. Genome Res (2011) 1.91
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2010) 1.89
Immunoglobulin somatic hypermutation. Annu Rev Genet (2007) 1.87
A comparative analysis of exome capture. Genome Biol (2011) 1.78
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res (1986) 1.75
Future medical applications of single-cell sequencing in cancer. Genome Med (2011) 1.72
A theoretical quantitative model for evolution of cancer chemotherapy resistance. Biol Direct (2010) 1.69
The relationship between growth rate, labelling index and histological type of human solid tumours. Eur J Cancer (1973) 1.68
Optimal deconvolution of transcriptional profiling data using quadratic programming with application to complex clinical blood samples. PLoS One (2011) 1.62
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Evolutionary biology of cancer. Trends Ecol Evol (2005) 1.58
Distance-based reconstruction of tree models for oncogenesis. J Comput Biol (2000) 1.55
Independent factor analysis. Neural Comput (1999) 1.53
Models, algorithms and programs for phylogeny reconciliation. Brief Bioinform (2011) 1.50
Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res (1991) 1.50
Taking advantage: high-affinity B cells in the germinal center have lower death rates, but similar rates of division, compared to low-affinity cells. J Immunol (2009) 1.49
Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med (2012) 1.41
Evolutionary theory of cancer. Ann N Y Acad Sci (2009) 1.41
Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet (2003) 1.35
Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research. PLoS One (2011) 1.32
Probabilistic analysis of gene expression measurements from heterogeneous tissues. Bioinformatics (2010) 1.31
Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach. BMC Bioinformatics (2010) 1.30
Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology (2005) 1.25
ISOLATE: a computational strategy for identifying the primary origin of cancers using high-throughput sequencing. Bioinformatics (2009) 1.22
Evolution of the cancer genome. Trends Genet (2012) 1.22
Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prev Res (Phila) (2011) 1.21
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut (2011) 1.20
Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol (2005) 1.20
Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15
Evolutionary dynamics of feedback escape and the development of stem-cell-driven cancers. Proc Natl Acad Sci U S A (2011) 1.14
Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res (1999) 1.12
Mutational pathway determines whether drug gradients accelerate evolution of drug-resistant cells. Phys Rev Lett (2012) 1.12
New probabilistic network models and algorithms for oncogenesis. J Comput Biol (2006) 1.11
Applying unmixing to gene expression data for tumor phylogeny inference. BMC Bioinformatics (2010) 1.09
Maximum likelihood estimation of oncogenetic tree models. Biostatistics (2004) 1.08
Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet (1995) 1.05
Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies. BMC Genomics (2011) 1.02
A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science (2003) 12.07
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57
XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell (2007) 4.93
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
An initial blueprint for myogenic differentiation. Genes Dev (2005) 4.22
A common set of gene regulatory networks links metabolism and growth inhibition. Mol Cell (2004) 3.37
PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell (2012) 3.28
Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc Natl Acad Sci U S A (2011) 2.48
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One (2009) 1.80
A role for mammalian Sin3 in permanent gene silencing. Mol Cell (2008) 1.59
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res (2008) 1.50
Picking ChIP-seq peak detectors for analyzing chromatin modification experiments. Nucleic Acids Res (2012) 1.49
Inter- and intra-combinatorial regulation by transcription factors and microRNAs. BMC Genomics (2007) 1.45
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst (2012) 1.42
Inhibition of nonsense-mediated RNA decay by the tumor microenvironment promotes tumorigenesis. Mol Cell Biol (2011) 1.42
Identification and correction of spurious spatial correlations in microarray data. Biotechniques (2003) 1.38
Characterizing disease states from topological properties of transcriptional regulatory networks. BMC Bioinformatics (2006) 1.27
Close proximity to Igh is a contributing factor to AID-mediated translocations. Mol Cell (2012) 1.23
Gene expression in mature neutrophils: early responses to inflammatory stimuli. J Leukoc Biol (2003) 1.23
Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line. Blood (2002) 1.22
Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res (2005) 1.20
The mammalian Sin3 proteins are required for muscle development and sarcomere specification. Mol Cell Biol (2010) 1.17
Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res (2011) 1.12
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res (2008) 1.11
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res (2009) 1.06
cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest (2004) 1.05
Gene expression in human neutrophils during activation and priming by bacterial lipopolysaccharide. J Cell Biochem (2003) 1.04
Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies. BMC Genomics (2011) 1.02
Two types of precursor cells in a multipotential hematopoietic cell line. Proc Natl Acad Sci U S A (2005) 1.02
RUNX transcription factor-mediated association of Cd4 and Cd8 enables coordinate gene regulation. Immunity (2011) 1.02
SFMBT1 functions with LSD1 to regulate expression of canonical histone genes and chromatin-related factors. Genes Dev (2013) 0.97
Unraveling condition specific gene transcriptional regulatory networks in Saccharomyces cerevisiae. BMC Bioinformatics (2006) 0.95
VDA, a method of choosing a better algorithm with fewer validations. PLoS One (2011) 0.94
The RAG2 C-terminus and ATM protect genome integrity by controlling antigen receptor gene cleavage. Nat Commun (2013) 0.92
Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Cancer Sci (2011) 0.91
Higher-order looping and nuclear organization of Tcra facilitate targeted rag cleavage and regulated rearrangement in recombination centers. Cell Rep (2013) 0.90
IL-7 functionally segregates the pro-B cell stage by regulating transcription of recombination mediators across cell cycle. J Immunol (2012) 0.85
Combined immunofluorescence and DNA FISH on 3D-preserved interphase nuclei to study changes in 3D nuclear organization. J Vis Exp (2013) 0.84
Ranking and combining multiple predictors without labeled data. Proc Natl Acad Sci U S A (2014) 0.84
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res (2010) 0.83
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clin Pathol (2013) 0.81
Comparative FAIRE-seq analysis reveals distinguishing features of the chromatin structure of ground state- and primed-pluripotent cells. Stem Cells (2015) 0.80
Integrated analysis of tumor samples sheds light on tumor heterogeneity. Yale J Biol Med (2012) 0.78
Arpeggio: harmonic compression of ChIP-seq data reveals protein-chromatin interaction signatures. Nucleic Acids Res (2013) 0.77
Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genomics (2014) 0.77
Response to Casellas et al. Mol Cell (2013) 0.76